

# RECAP IQ SERIES

A GOOD DEAL - FASTER. WITH ENHANCED CONTENT, ANALYTICS AND VISUALIZATION TOOLS

Whether you are looking to buy, sell, or license a drug candidate Recap IQ provides you with data and analysis to support your deal making and pipeline evaluations. Our series of content, analytics and visualization tools allow you to quickly tabulate deal comparables, examine alternative deal structures, and evaluate drugs in biopharma pipelines with respect to probabilities of success, termination analysis and development timelines.

## DEAL BUILDER™

Deals are typically subordinate to strategic plans that include revenue, control, and timing goals. With Deal Builder, the core of Recap IQ, you can:

- Identify deal comparables, deal structure alternatives, and critical deal terms
- Locate potential partnership opportunities and conduct due diligence

## Data and Analytics:

- 40,000+ Alliance Summaries
- 2,800+ Contract Analyses
- 1,700+ Deal Snapshots
- 362 index criteria
- 15,800+ licensees and licensors
- Custom Excel reports
- 28,200+ contracts

## DEAL BUILDER SELECT

Gain further ground on your deal with Deal Builder Select. Available as part of your Recap IQ subscription, Deal Builder Select helps you easily:

- Find precise comparables
- Understand a set of deals in minutes, not hours
- Create your own custom analytics



Valuation Analyzer

## Data and Analytics

- Smart Summaries that provide the best “decoded” analysis of announced deals available
- 12 key data fields that have been re-indexed with new values to retrieve precise result sets
- New standardized Deal Snapshot that utilizes new high quality data fields including updated financial fields
- Enhanced Excel reports, including presentation tables, user defined pivot tables, and graphical analysis of key financials
- 49 new data fields in the Alliance Summary, including product names, mechanisms of action, asset type, and M&A data related to the target company
- 34 updated fields, including all financial payments, licensees and licensors, transaction types, and Deal Subject

## VALUATION ANALYZER™

Deal terms for commercialized products can be difficult to come by and difficult to analyze. The additional Recap IQ analytics module, Valuation Analyzer, provides you with ready analysis and insights of our collection of 2,600+ deals with unredacted SEC contracts. A proprietary algorithm calculates effective royalty rates that enable you to compare disparate deals with varying royalty rates, transfer prices and profit splits at the \$200M, \$500M and \$1B sales levels.

- Compare deals to find market rates for royalties, transfer prices, and profit splits
- Find critical deal terms from unredacted contracts

**Octreolin (octreotide) oral formulation for acromegaly and neuroendocrine tumors worldwide**

**Chiasma**

**Deal Builder**

completion of the pivotal Phase III trial for acromegaly

- Developed the formulation using its Transient Permeability Enhancer technology
- Phase III data are expected in 3Q2013; MAA and NDA submissions are planned for 1Q2014

Rights to commercialize octreotide, a somatostatin analog, formulated with Chiasma's TPE oral formulation technology

Therapeutic Area: Endocrine/Metabolic

Technology: Drug Delivery - Oral

Market: Worldwide

State III Grant, Reformulation License Exclusivity

Exclusive # Products/Options: 1

**Roche**

Roche's Genentech unit will market the product in the U.S. after approval.


**Total Deal Size (USD): \$595M**

<ul style="list-style-type: none"> <li>• \$65M</li> <li>• \$530M</li> </ul>	<ul style="list-style-type: none"> <li>• \$595M</li> <li>• Royalty</li> </ul>
---	---

Source: Recap IQ DEAL builder™

Announced: 02/2013





Development Optimizer

#### Data and Analytics:

- 2,600+ Alliance Summaries and contracts
- 1,100+ Contract Analyses
- 382 index criteria
- Custom Excel reports

#### DEVELOPMENT OPTIMIZER™

Available separately or as part of your Recap IQ subscription, Development Optimizer uses highly curated pipeline data from 321 leading biotech companies, you can estimate a drug's probability of success, compare attrition advancement rates and reasons for termination and determine which drugs are unpartnered.

- Study and compare attrition and advancement rates and reasons for termination
- Identify potential partners based on development and regulatory performance

#### Data and Analytics:

- 2,800+ project records, updated daily
- 7,900+ clinical trials correlated with results, regulatory status, and review times
- 20,700+ corporate press releases
- Graphical and tabular development timelines with detailed milestone information
- 210 index criteria

#### FOR MORE INFORMATION

Learn how Recap can help you do a good deal faster, visit [www.recap.com](http://www.recap.com)

#### ABOUT RECAP

Recap from Thomson Reuters aims to provide analysis and advice for biopharmaceutical business development. Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture firms. More than 1,500 organizations utilize Recap's data services. Recap combines extensive deals analysis experience with the breadth of Life Sciences service offerings from Thomson Reuters creating a powerful combination for clients.

